Anti-M. hominis antibodies for refractory septic arthritis

Phase 1, open-label, single-arm trial of anti-mycoplasma hominis antibodies in Mycoplasma hominis infection and septic arthritis, sponsored by Brigham and Women's Hospital. Primary endpoints: Presence or absence of mycoplasma hominis cultured from joint and wound fluid at 1 year, Patency of fistula as assessed by clinical exam at 1 year and 1 more. Started Apr 2016; status: completed.